Ventyx Biosciences Announces Preclinical Data For CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal Of Obesity And Improvements In Cardiometabolic And Inflammatory Markers

6/5/24 4:01:55 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VTYX alert in real time by email

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice

Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone

Get the next $VTYX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VTYX

Date	Price Target	Rating	Analyst
3/12/2024	$12.00	Perform → Outperform	Oppenheimer
3/12/2024	$7.00 → $16.00	Equal Weight → Overweight	Wells Fargo
11/7/2023	$46.00 → $6.00	Overweight → Equal-Weight	Morgan Stanley
11/7/2023		Outperform → Perform	Oppenheimer
11/7/2023		Buy → Neutral	H.C. Wainwright
11/7/2023	$6.00	Buy → Hold	Stifel
11/7/2023	$77.00 → $8.00	Overweight → Equal Weight	Wells Fargo
6/14/2023	$63.00	Outperform	Credit Suisse

More analyst ratings

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi
5/9/24 4:01:00 PM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)
5/2/24 4:05:00 PM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a partner or other nondilutive financing for pivotal Phase 3 trial Based on pipeline reprioritization and recent PIPE financing, Ventyx expects its current cash, cash equivalents and marketable securit
3/11/24 7:00:00 AM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care

$VTYX
Press Releases

Fastest customizable press release news feed in the world

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson's disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results anticipated in H2 2025 Cash balance of $274.8M as of September 30, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therap
11/7/24 4:05:00 PM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative colitis was presented on October 15, 2024 during the United European Gastroenterology (UEG) Week meeting in Vienna, Austria. "We are excited to present the new long-term extension data from the tamuzimod Phase 2 trial in patients with ulcerative colitis at UEG Week," said Raju Mohan, P
10/15/24 8:00:00 AM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of $3.8243 per share of common stock, pursuant to which Sanofi will purchase 70,601 of the Company's Series A non-voting convertible preferred stock, each share of which is initially convertible into 100 shares of common stock. The closing of the transaction is expected to occur on September 23, 2024. "
9/23/24 8:00:00 AM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care

$VTYX
Leadership Updates

Live Leadership Updates

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie
8/8/24 4:01:00 PM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to
5/16/24 8:00:00 AM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors. Dr. Hulme and Ms. Cadoret-Manier are both successful executives who each bring a wealth of knowledge from more than 30 years of experience in biotech and pharmaceutical drug development and commercialization. Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeo
1/12/23 8:00:00 AM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care

$VTYX
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
6/13/24 6:41:28 AM ET
$VTYX
Biotechnology: Pharmaceutical Preparations
Health Care
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.1% on Thursday. The Dow traded up 0.06% to 38,830.40 while the NASDAQ fell 0.16% to 17,160.31. The S&P 500 also fell, dropping, 0.12% to 5,347.42. . Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields Leading and Lagging SectorsConsumer discretionary shares rose by 0.8% on Thursday. In trading on Thursday, utilities shares fell by 0.8%. Top Headline The J. M. Smucker Company (NYSE:SJM) shares gained around 5% on Thursday after the company posted upbeat quarterly earnings. The company reported a fourth-quarter FY
6/6/24 2:45:57 PM ET
$ASNS
$FRGT
$ICU
$REPL
Telecommunications Equipment
Telecommunications
Professional Services
Consumer Discretionary
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
6/6/24 1:39:18 PM ET
$AEMD
$AIRJ
$AONC
$ASNS
Medical/Dental Instruments
Health Care
Industrial Machinery/Components
Industrials

Ventyx Biosciences Announces Preclinical Data For CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal Of Obesity And Improvements In Cardiometabolic And Inflammatory Markers

Chat with this insight

Recent Analyst Ratings for $VTYX

$VTYX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

Amendment: SEC Form SC 13D/A filed by Ventyx Biosciences Inc.

SEC Form SC 13G filed by Ventyx Biosciences Inc.

$VTYX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Gonzales Roy claimed ownership of 743 shares (SEC Form 3)

SEC Form 4 filed by Chief Medical Officer Forman Mark S

SEC Form 3 filed by new insider Forman Mark S

$VTYX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$VTYX Financials

Live finance-specific insights

Ventyx Biosciences upgraded by Oppenheimer with a new price target

Ventyx Biosciences upgraded by Wells Fargo with a new price target

Ventyx Biosciences downgraded by Morgan Stanley with a new price target

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

$VTYX Press Releases

Fastest customizable press release news feed in the world

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

$VTYX Leadership Updates

Live Leadership Updates

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

$VTYX SEC Filings

SEC Form S-3 filed by Ventyx Biosciences Inc.

SEC Form 10-Q filed by Ventyx Biosciences Inc.

Ventyx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

$VTYX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target

S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Recent Analyst Ratings for
$VTYX

$VTYX
Large Ownership Changes

$VTYX
Insider Trading

$VTYX
Analyst Ratings

$VTYX
Financials

$VTYX
Press Releases

$VTYX
Leadership Updates

$VTYX
SEC Filings

$VTYX
Market Insights